Our pipeline

Product candidate
Cancer Indication
Combination with
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Next expected event
Pemetrexed/
cisplatin
New year
2019-20

Randomized data
KEYTRUDA
1H 2020
Part 2 data
ONCOS-102
IMFINZI® (Collab. with: Ludwig, CRI & AZ)
Update by collaborator
ONCOS-102
DCVAC (Collab. with: SOTIO)
Update by collaborator
Undisclosed
-
2H 2019
First pre-clinical data
Cancer Indication: Mesothelioma ODD
Combination with: Pemetrexed/
cisplatin

Product candidate: ONCOS-102
Next expected event: New year 2019-20, Randomized data
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Melanoma
Combination with: KEYTRUDA
Product candidate: ONCOS-102
Next expected event: 1H 2020, Part 2 data
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Peritoneal
ODD*

Combination with: IMFINZI® (Collab. with: Ludwig, CRI & AZ)
Product candidate: ONCOS-102
Next expected event: Update by collaborator
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Prostate
Combination with: DCVAC (Collab. with: SOTIO)
Product candidate: ONCOS-102
Next expected event: Update by collaborator
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Undisclosed
Combination with: -
Product candidate: ONCOS – 211, ONCOS – 212, ONCOS – 214
Next expected event: 2H 2019, First pre-clinical data
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Resected Panceras
Combination with: Gemcitabine
Product candidate: TG01
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Colorectal
Combination with: KEYTRUDA
Product candidate: TG02
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication:
Combination with: CPI synergy
TG + PD-1

Product candidate: TG02
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Ongoing collaborator sponsored trials

ODD=Orphan Drug Designation
ODD*=ODD in Ovarian Cancer Perioteneal Subpopulation